| |
Public Act 101-0666 Public Act 0666 101ST GENERAL ASSEMBLY |
Public Act 101-0666 | HB2488 Enrolled | LRB101 07727 CPF 52776 b |
|
| AN ACT concerning regulation.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The Illinois Controlled Substances Act is | amended by changing Section 102 and by adding Section 220 as | follows: | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) | Sec. 102. Definitions. As used in this Act, unless the | context
otherwise requires:
| (a) "Addict" means any person who habitually uses any drug, | chemical,
substance or dangerous drug other than alcohol so as | to endanger the public
morals, health, safety or welfare or who | is so far addicted to the use of a
dangerous drug or controlled | substance other than alcohol as to have lost
the power of self | control with reference to his or her addiction.
| (b) "Administer" means the direct application of a | controlled
substance, whether by injection, inhalation, | ingestion, or any other
means, to the body of a patient, | research subject, or animal (as
defined by the Humane | Euthanasia in Animal Shelters Act) by:
| (1) a practitioner (or, in his or her presence, by his | or her authorized agent),
| (2) the patient or research subject pursuant to an |
| order, or
| (3) a euthanasia technician as defined by the Humane | Euthanasia in
Animal Shelters Act.
| (c) "Agent" means an authorized person who acts on behalf | of or at
the direction of a manufacturer, distributor, | dispenser, prescriber, or practitioner. It does not
include a | common or contract carrier, public warehouseman or employee of
| the carrier or warehouseman.
| (c-1) "Anabolic Steroids" means any drug or hormonal | substance,
chemically and pharmacologically related to | testosterone (other than
estrogens, progestins, | corticosteroids, and dehydroepiandrosterone),
and includes:
| (i) 3[beta],17-dihydroxy-5a-androstane, | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, | (iii) 5[alpha]-androstan-3,17-dione, | (iv) 1-androstenediol (3[beta], | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | (v) 1-androstenediol (3[alpha], | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | (vi) 4-androstenediol | (3[beta],17[beta]-dihydroxy-androst-4-ene), | (vii) 5-androstenediol | (3[beta],17[beta]-dihydroxy-androst-5-ene), | (viii) 1-androstenedione | ([5alpha]-androst-1-en-3,17-dione), | (ix) 4-androstenedione |
| (androst-4-en-3,17-dione), | (x) 5-androstenedione | (androst-5-en-3,17-dione), | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- | hydroxyandrost-4-en-3-one), | (xii) boldenone (17[beta]-hydroxyandrost- | 1,4,-diene-3-one), | (xiii) boldione (androsta-1,4- | diene-3,17-dione), | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 | [beta]-hydroxyandrost-4-en-3-one), | (xv) clostebol (4-chloro-17[beta]- | hydroxyandrost-4-en-3-one), | (xvi) dehydrochloromethyltestosterone (4-chloro- | 17[beta]-hydroxy-17[alpha]-methyl- | androst-1,4-dien-3-one), | (xvii) desoxymethyltestosterone | (17[alpha]-methyl-5[alpha] | -androst-2-en-17[beta]-ol)(a.k.a., madol), | (xviii) [delta]1-dihydrotestosterone (a.k.a. | '1-testosterone') (17[beta]-hydroxy- | 5[alpha]-androst-1-en-3-one), | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- | androstan-3-one), | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- | 5[alpha]-androstan-3-one), |
| (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- | hydroxyestr-4-ene), | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], | 17[beta]-dihydroxyandrost-1,4-dien-3-one), | (xxiv) furazabol (17[alpha]-methyl-17[beta]- | hydroxyandrostano[2,3-c]-furazan), | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- | androst-4-en-3-one), | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- | dihydroxy-estr-4-en-3-one), | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- | hydroxy-5-androstan-3-one), | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- | [5a]-androstan-3-one), | (xxx) methandienone (17[alpha]-methyl-17[beta]- | hydroxyandrost-1,4-dien-3-one), | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- | dihydroxyandrost-5-ene), | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- | 5[alpha]-androst-1-en-3-one), | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- | dihydroxy-5a-androstane, | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy |
| -5a-androstane, | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- | dihydroxyandrost-4-ene), | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- | hydroxyestra-4,9(10)-dien-3-one), | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- | hydroxyestra-4,9-11-trien-3-one), | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- | hydroxyandrost-4-en-3-one), | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- | hydroxyestr-4-en-3-one), | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- | 1-testosterone'), | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- | dihydroxyestr-4-ene), | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- | dihydroxyestr-4-ene), | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- | dihydroxyestr-5-ene), | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- | dihydroxyestr-5-ene), |
| (xlvii) 19-nor-4,9(10)-androstadienedione | (estra-4,9(10)-diene-3,17-dione), | (xlviii) 19-nor-4-androstenedione (estr-4- | en-3,17-dione), | (xlix) 19-nor-5-androstenedione (estr-5- | en-3,17-dione), | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- | hydroxygon-4-en-3-one), | (li) norclostebol (4-chloro-17[beta]- | hydroxyestr-4-en-3-one), | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- | hydroxyestr-4-en-3-one), | (liii) normethandrolone (17[alpha]-methyl-17[beta]- | hydroxyestr-4-en-3-one), | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- | 2-oxa-5[alpha]-androstan-3-one), | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- | dihydroxyandrost-4-en-3-one), | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- | (5[alpha]-androst-1-en-3-one), | (lix) testolactone (13-hydroxy-3-oxo-13,17- | secoandrosta-1,4-dien-17-oic |
| acid lactone), | (lx) testosterone (17[beta]-hydroxyandrost- | 4-en-3-one), | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- | diethyl-17[beta]-hydroxygon- | 4,9,11-trien-3-one), | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, | 11-trien-3-one).
| Any person who is otherwise lawfully in possession of an | anabolic
steroid, or who otherwise lawfully manufactures, | distributes, dispenses,
delivers, or possesses with intent to | deliver an anabolic steroid, which
anabolic steroid is | expressly intended for and lawfully allowed to be
administered | through implants to livestock or other nonhuman species, and
| which is approved by the Secretary of Health and Human Services | for such
administration, and which the person intends to | administer or have
administered through such implants, shall | not be considered to be in
unauthorized possession or to | unlawfully manufacture, distribute, dispense,
deliver, or | possess with intent to deliver such anabolic steroid for
| purposes of this Act.
| (d) "Administration" means the Drug Enforcement | Administration,
United States Department of Justice, or its | successor agency.
| (d-5) "Clinical Director, Prescription Monitoring Program" | means a Department of Human Services administrative employee |
| licensed to either prescribe or dispense controlled substances | who shall run the clinical aspects of the Department of Human | Services Prescription Monitoring Program and its Prescription | Information Library. | (d-10) "Compounding" means the preparation and mixing of | components, excluding flavorings, (1) as the result of a | prescriber's prescription drug order or initiative based on the | prescriber-patient-pharmacist relationship in the course of | professional practice or (2) for the purpose of, or incident | to, research, teaching, or chemical analysis and not for sale | or dispensing. "Compounding" includes the preparation of drugs | or devices in anticipation of receiving prescription drug | orders based on routine, regularly observed dispensing | patterns. Commercially available products may be compounded | for dispensing to individual patients only if both of the | following conditions are met: (i) the commercial product is not | reasonably available from normal distribution channels in a | timely manner to meet the patient's needs and (ii) the | prescribing practitioner has requested that the drug be | compounded. | (e) "Control" means to add a drug or other substance, or | immediate
precursor, to a Schedule whether by
transfer from | another Schedule or otherwise.
| (f) "Controlled Substance" means (i) a drug, substance, | immediate
precursor, or synthetic drug in the Schedules of | Article II of this Act or (ii) a drug or other substance, or |
| immediate precursor, designated as a controlled substance by | the Department through administrative rule. The term does not | include distilled spirits, wine, malt beverages, or tobacco, as | those terms are
defined or used in the Liquor Control Act of | 1934 and the Tobacco Products Tax
Act of 1995.
| (f-5) "Controlled substance analog" means a substance: | (1) the chemical structure of which is substantially | similar to the chemical structure of a controlled substance | in Schedule I or II; | (2) which has a stimulant, depressant, or | hallucinogenic effect on the central nervous system that is | substantially similar to or greater than the stimulant, | depressant, or hallucinogenic effect on the central | nervous system of a controlled substance in Schedule I or | II; or | (3) with respect to a particular person, which such | person represents or intends to have a stimulant, | depressant, or hallucinogenic effect on the central | nervous system that is substantially similar to or greater | than the stimulant, depressant, or hallucinogenic effect | on the central nervous system of a controlled substance in | Schedule I or II. | (g) "Counterfeit substance" means a controlled substance, | which, or
the container or labeling of which, without | authorization bears the
trademark, trade name, or other | identifying mark, imprint, number or
device, or any likeness |
| thereof, of a manufacturer, distributor, or
dispenser other | than the person who in fact manufactured, distributed,
or | dispensed the substance.
| (h) "Deliver" or "delivery" means the actual, constructive | or
attempted transfer of possession of a controlled substance, | with or
without consideration, whether or not there is an | agency relationship.
| (i) "Department" means the Illinois Department of Human | Services (as
successor to the Department of Alcoholism and | Substance Abuse) or its successor agency.
| (j) (Blank).
| (k) "Department of Corrections" means the Department of | Corrections
of the State of Illinois or its successor agency.
| (l) "Department of Financial and Professional Regulation" | means the Department
of Financial and Professional Regulation | of the State of Illinois or its successor agency.
| (m) "Depressant" means any drug that (i) causes an overall | depression of central nervous system functions, (ii) causes | impaired consciousness and awareness, and (iii) can be | habit-forming or lead to a substance abuse problem, including | but not limited to alcohol, cannabis and its active principles | and their analogs, benzodiazepines and their analogs, | barbiturates and their analogs, opioids (natural and | synthetic) and their analogs, and chloral hydrate and similar | sedative hypnotics.
| (n) (Blank).
|
| (o) "Director" means the Director of the Illinois State | Police or his or her designated agents.
| (p) "Dispense" means to deliver a controlled substance to | an
ultimate user or research subject by or pursuant to the | lawful order of
a prescriber, including the prescribing, | administering, packaging,
labeling, or compounding necessary | to prepare the substance for that
delivery.
| (q) "Dispenser" means a practitioner who dispenses.
| (r) "Distribute" means to deliver, other than by | administering or
dispensing, a controlled substance.
| (s) "Distributor" means a person who distributes.
| (t) "Drug" means (1) substances recognized as drugs in the | official
United States Pharmacopoeia, Official Homeopathic | Pharmacopoeia of the
United States, or official National | Formulary, or any supplement to any
of them; (2) substances | intended for use in diagnosis, cure, mitigation,
treatment, or | prevention of disease in man or animals; (3) substances
(other | than food) intended to affect the structure of any function of
| the body of man or animals and (4) substances intended for use | as a
component of any article specified in clause (1), (2), or | (3) of this
subsection. It does not include devices or their | components, parts, or
accessories.
| (t-3) "Electronic health record" or "EHR" means an | electronic record of health-related information on an | individual that is created, gathered, managed, and consulted by | authorized health care clinicians and staff. |
| (t-3.5) "Electronic health record system" or "EHR system" | means any computer-based system or combination of federally | certified Health IT Modules (defined at 42 CFR 170.102 or its | successor) used as a repository for electronic health records | and accessed or updated by a prescriber or authorized surrogate | in the ordinary course of his or her medical practice. For | purposes of connecting to the Prescription Information Library | maintained by the Bureau of Pharmacy and Clinical Support | Systems or its successor, an EHR system may connect to the | Prescription Information Library directly or through all or | part of a computer program or system that is a federally | certified Health IT Module maintained by a third party and used | by the EHR system to secure access to the database. | (t-4) "Emergency medical services personnel" has the | meaning ascribed to it in the Emergency Medical Services (EMS) | Systems Act. | (t-5) "Euthanasia agency" means
an entity certified by the | Department of Financial and Professional Regulation for the
| purpose of animal euthanasia that holds an animal control | facility license or
animal
shelter license under the Animal | Welfare Act. A euthanasia agency is
authorized to purchase, | store, possess, and utilize Schedule II nonnarcotic and
| Schedule III nonnarcotic drugs for the sole purpose of animal | euthanasia.
| (t-10) "Euthanasia drugs" means Schedule II or Schedule III | substances
(nonnarcotic controlled substances) that are used |
| by a euthanasia agency for
the purpose of animal euthanasia.
| (u) "Good faith" means the prescribing or dispensing of a | controlled
substance by a practitioner in the regular course of | professional
treatment to or for any person who is under his or | her treatment for a
pathology or condition other than that | individual's physical or
psychological dependence upon or | addiction to a controlled substance,
except as provided herein: | and application of the term to a pharmacist
shall mean the | dispensing of a controlled substance pursuant to the
| prescriber's order which in the professional judgment of the | pharmacist
is lawful. The pharmacist shall be guided by | accepted professional
standards including, but not limited to | the following, in making the
judgment:
| (1) lack of consistency of prescriber-patient | relationship,
| (2) frequency of prescriptions for same drug by one | prescriber for
large numbers of patients,
| (3) quantities beyond those normally prescribed,
| (4) unusual dosages (recognizing that there may be | clinical circumstances where more or less than the usual | dose may be used legitimately),
| (5) unusual geographic distances between patient, | pharmacist and
prescriber,
| (6) consistent prescribing of habit-forming drugs.
| (u-0.5) "Hallucinogen" means a drug that causes markedly | altered sensory perception leading to hallucinations of any |
| type. | (u-1) "Home infusion services" means services provided by a | pharmacy in
compounding solutions for direct administration to | a patient in a private
residence, long-term care facility, or | hospice setting by means of parenteral,
intravenous, | intramuscular, subcutaneous, or intraspinal infusion.
| (u-5) "Illinois State Police" means the State
Police of the | State of Illinois, or its successor agency. | (v) "Immediate precursor" means a substance:
| (1) which the Department has found to be and by rule | designated as
being a principal compound used, or produced | primarily for use, in the
manufacture of a controlled | substance;
| (2) which is an immediate chemical intermediary used or | likely to
be used in the manufacture of such controlled | substance; and
| (3) the control of which is necessary to prevent, | curtail or limit
the manufacture of such controlled | substance.
| (w) "Instructional activities" means the acts of teaching, | educating
or instructing by practitioners using controlled | substances within
educational facilities approved by the State | Board of Education or
its successor agency.
| (x) "Local authorities" means a duly organized State, | County or
Municipal peace unit or police force.
| (y) "Look-alike substance" means a substance, other than a |
| controlled
substance which (1) by overall dosage unit | appearance, including shape,
color, size, markings or lack | thereof, taste, consistency, or any other
identifying physical | characteristic of the substance, would lead a reasonable
person | to believe that the substance is a controlled substance, or (2) | is
expressly or impliedly represented to be a controlled | substance or is
distributed under circumstances which would | lead a reasonable person to
believe that the substance is a | controlled substance. For the purpose of
determining whether | the representations made or the circumstances of the
| distribution would lead a reasonable person to believe the | substance to be
a controlled substance under this clause (2) of | subsection (y), the court or
other authority may consider the | following factors in addition to any other
factor that may be | relevant:
| (a) statements made by the owner or person in control | of the substance
concerning its nature, use or effect;
| (b) statements made to the buyer or recipient that the | substance may
be resold for profit;
| (c) whether the substance is packaged in a manner | normally used for the
illegal distribution of controlled | substances;
| (d) whether the distribution or attempted distribution | included an
exchange of or demand for money or other | property as consideration, and
whether the amount of the | consideration was substantially greater than the
|
| reasonable retail market value of the substance.
| Clause (1) of this subsection (y) shall not apply to a | noncontrolled
substance in its finished dosage form that was | initially introduced into
commerce prior to the initial | introduction into commerce of a controlled
substance in its | finished dosage form which it may substantially resemble.
| Nothing in this subsection (y) prohibits the dispensing or | distributing
of noncontrolled substances by persons authorized | to dispense and
distribute controlled substances under this | Act, provided that such action
would be deemed to be carried | out in good faith under subsection (u) if the
substances | involved were controlled substances.
| Nothing in this subsection (y) or in this Act prohibits the | manufacture,
preparation, propagation, compounding, | processing, packaging, advertising
or distribution of a drug or | drugs by any person registered pursuant to
Section 510 of the | Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
| (y-1) "Mail-order pharmacy" means a pharmacy that is | located in a state
of the United States that delivers, | dispenses or
distributes, through the United States Postal | Service or other common
carrier, to Illinois residents, any | substance which requires a prescription.
| (z) "Manufacture" means the production, preparation, | propagation,
compounding, conversion or processing of a | controlled substance other than methamphetamine, either
| directly or indirectly, by extraction from substances of |
| natural origin,
or independently by means of chemical | synthesis, or by a combination of
extraction and chemical | synthesis, and includes any packaging or
repackaging of the | substance or labeling of its container, except that
this term | does not include:
| (1) by an ultimate user, the preparation or compounding | of a
controlled substance for his or her own use; or
| (2) by a practitioner, or his or her authorized agent | under his or her
supervision, the preparation, | compounding, packaging, or labeling of a
controlled | substance:
| (a) as an incident to his or her administering or | dispensing of a
controlled substance in the course of | his or her professional practice; or
| (b) as an incident to lawful research, teaching or | chemical
analysis and not for sale.
| (z-1) (Blank).
| (z-5) "Medication shopping" means the conduct prohibited | under subsection (a) of Section 314.5 of this Act. | (z-10) "Mid-level practitioner" means (i) a physician | assistant who has been delegated authority to prescribe through | a written delegation of authority by a physician licensed to | practice medicine in all of its branches, in accordance with | Section 7.5 of the Physician Assistant Practice Act of 1987, | (ii) an advanced practice registered nurse who has been | delegated authority to prescribe through a written delegation |
| of authority by a physician licensed to practice medicine in | all of its branches or by a podiatric physician, in accordance | with Section 65-40 of the Nurse Practice Act, (iii) an advanced | practice registered nurse certified as a nurse practitioner, | nurse midwife, or clinical nurse specialist who has been | granted authority to prescribe by a hospital affiliate in | accordance with Section 65-45 of the Nurse Practice Act, (iv) | an animal euthanasia agency, or (v) a prescribing psychologist. | (aa) "Narcotic drug" means any of the following, whether | produced
directly or indirectly by extraction from substances | of vegetable origin,
or independently by means of chemical | synthesis, or by a combination of
extraction and chemical | synthesis:
| (1) opium, opiates, derivatives of opium and opiates, | including their isomers, esters, ethers, salts, and salts | of isomers, esters, and ethers, whenever the existence of | such isomers, esters, ethers, and salts is possible within | the specific chemical designation; however the term | "narcotic drug" does not include the isoquinoline | alkaloids of opium;
| (2) (blank);
| (3) opium poppy and poppy straw;
| (4) coca leaves, except coca leaves and extracts of | coca leaves from which substantially all of the cocaine and | ecgonine, and their isomers, derivatives and salts, have | been removed;
|
| (5) cocaine, its salts, optical and geometric isomers, | and salts of isomers; | (6) ecgonine, its derivatives, their salts, isomers, | and salts of isomers; | (7) any compound, mixture, or preparation which | contains any quantity of any of the substances referred to | in subparagraphs (1) through (6). | (bb) "Nurse" means a registered nurse licensed under the
| Nurse Practice Act.
| (cc) (Blank).
| (dd) "Opiate" means any substance having an addiction | forming or
addiction sustaining liability similar to morphine | or being capable of
conversion into a drug having addiction | forming or addiction sustaining
liability.
| (ee) "Opium poppy" means the plant of the species Papaver
| somniferum L., except its seeds.
| (ee-5) "Oral dosage" means a tablet, capsule, elixir, or | solution or other liquid form of medication intended for | administration by mouth, but the term does not include a form | of medication intended for buccal, sublingual, or transmucosal | administration. | (ff) "Parole and Pardon Board" means the Parole and Pardon | Board of
the State of Illinois or its successor agency.
| (gg) "Person" means any individual, corporation, | mail-order pharmacy,
government or governmental subdivision or | agency, business trust, estate,
trust, partnership or |
| association, or any other entity.
| (hh) "Pharmacist" means any person who holds a license or | certificate of
registration as a registered pharmacist, a local | registered pharmacist
or a registered assistant pharmacist | under the Pharmacy Practice Act.
| (ii) "Pharmacy" means any store, ship or other place in | which
pharmacy is authorized to be practiced under the Pharmacy | Practice Act.
| (ii-5) "Pharmacy shopping" means the conduct prohibited | under subsection (b) of Section 314.5 of this Act. | (ii-10) "Physician" (except when the context otherwise | requires) means a person licensed to practice medicine in all | of its branches. | (jj) "Poppy straw" means all parts, except the seeds, of | the opium
poppy, after mowing.
| (kk) "Practitioner" means a physician licensed to practice | medicine in all
its branches, dentist, optometrist, podiatric | physician,
veterinarian, scientific investigator, pharmacist, | physician assistant,
advanced practice registered nurse,
| licensed practical
nurse, registered nurse, emergency medical | services personnel, hospital, laboratory, or pharmacy, or | other
person licensed, registered, or otherwise lawfully | permitted by the
United States or this State to distribute, | dispense, conduct research
with respect to, administer or use | in teaching or chemical analysis, a
controlled substance in the | course of professional practice or research.
|
| (ll) "Pre-printed prescription" means a written | prescription upon which
the designated drug has been indicated | prior to the time of issuance; the term does not mean a written | prescription that is individually generated by machine or | computer in the prescriber's office.
| (mm) "Prescriber" means a physician licensed to practice | medicine in all
its branches, dentist, optometrist, | prescribing psychologist licensed under Section 4.2 of the | Clinical Psychologist Licensing Act with prescriptive | authority delegated under Section 4.3 of the Clinical | Psychologist Licensing Act, podiatric physician, or
| veterinarian who issues a prescription, a physician assistant | who
issues a
prescription for a controlled substance
in | accordance
with Section 303.05, a written delegation, and a | written collaborative agreement required under Section 7.5
of | the
Physician Assistant Practice Act of 1987, an advanced | practice registered
nurse with prescriptive authority | delegated under Section 65-40 of the Nurse Practice Act and in | accordance with Section 303.05, a written delegation,
and a | written
collaborative agreement under Section 65-35 of the | Nurse Practice Act, an advanced practice registered nurse | certified as a nurse practitioner, nurse midwife, or clinical | nurse specialist who has been granted authority to prescribe by | a hospital affiliate in accordance with Section 65-45 of the | Nurse Practice Act and in accordance with Section 303.05, or an | advanced practice registered nurse certified as a nurse |
| practitioner, nurse midwife, or clinical nurse specialist who | has full practice authority pursuant to Section 65-43 of the | Nurse Practice Act.
| (nn) "Prescription" means a written, facsimile, or oral | order, or an electronic order that complies with applicable | federal requirements,
of
a physician licensed to practice | medicine in all its branches,
dentist, podiatric physician or | veterinarian for any controlled
substance, of an optometrist in | accordance with Section 15.1 of the Illinois Optometric | Practice Act of 1987, of a prescribing psychologist licensed | under Section 4.2 of the Clinical Psychologist Licensing Act | with prescriptive authority delegated under Section 4.3 of the | Clinical Psychologist Licensing Act, of a physician assistant | for a
controlled substance
in accordance with Section 303.05, a | written delegation, and a written collaborative agreement | required under
Section 7.5 of the
Physician Assistant Practice | Act of 1987, of an advanced practice registered
nurse with | prescriptive authority delegated under Section 65-40 of the | Nurse Practice Act who issues a prescription for a
controlled | substance in accordance
with
Section 303.05, a written | delegation, and a written collaborative agreement under | Section 65-35 of the Nurse Practice Act, of an advanced | practice registered nurse certified as a nurse practitioner, | nurse midwife, or clinical nurse specialist who has been | granted authority to prescribe by a hospital affiliate in | accordance with Section 65-45 of the Nurse Practice Act and in |
| accordance with Section 303.05 when required by law, or of an | advanced practice registered nurse certified as a nurse | practitioner, nurse midwife, or clinical nurse specialist who | has full practice authority pursuant to Section 65-43 of the | Nurse Practice Act.
| (nn-5) "Prescription Information Library" (PIL) means an | electronic library that contains reported controlled substance | data. | (nn-10) "Prescription Monitoring Program" (PMP) means the | entity that collects, tracks, and stores reported data on | controlled substances and select drugs pursuant to Section 316. | (oo) "Production" or "produce" means manufacture, | planting,
cultivating, growing, or harvesting of a controlled | substance other than methamphetamine.
| (pp) "Registrant" means every person who is required to | register
under Section 302 of this Act.
| (qq) "Registry number" means the number assigned to each | person
authorized to handle controlled substances under the | laws of the United
States and of this State.
| (qq-5) "Secretary" means, as the context requires, either | the Secretary of the Department or the Secretary of the | Department of Financial and Professional Regulation, and the | Secretary's designated agents. | (rr) "State" includes the State of Illinois and any state, | district,
commonwealth, territory, insular possession thereof, | and any area
subject to the legal authority of the United |
| States of America.
| (rr-5) "Stimulant" means any drug that (i) causes an | overall excitation of central nervous system functions, (ii) | causes impaired consciousness and awareness, and (iii) can be | habit-forming or lead to a substance abuse problem, including | but not limited to amphetamines and their analogs, | methylphenidate and its analogs, cocaine, and phencyclidine | and its analogs. | (rr-10) "Synthetic drug" includes, but is not limited to, | any synthetic cannabinoids or piperazines or any synthetic | cathinones as provided for in Schedule I. | (ss) "Ultimate user" means a person who lawfully possesses | a
controlled substance for his or her own use or for the use of | a member of his or her
household or for administering to an | animal owned by him or her or by a member
of his or her | household.
| (Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15; | 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16; | 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff. | 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. 8-14-18 .)
| (720 ILCS 570/220 new) | Sec. 220. Electronic health record systems. The Bureau of | Pharmacy and Clinical Support Systems shall establish a form to | allow EHR systems to certify the identity of a third party that | will provide access to the Prescription Information Library for |
| the EHR system using all or part of a computer program or | system that is a federally certified Health IT Module for the | EHR system. Before the Health IT Module is permitted to connect | to the Prescription Information Library, it must enter into a | business associate agreement with the EHR system that requires | the Health IT Module to agree to adhere to all requirements | imposed on the EHR system by the laws of this State, including | data privacy and security obligations that the Bureau otherwise | imposes on EHR systems.
|
Effective Date: 1/1/2022
|
|
|